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Background: There are no data available about effectiveness of Nasal High-flow (NHF)in chronic respiratory insufficiency.
Methods: Eleven COPD patients with stable hypercapnia were adjusted to NHF-system with a flow of 20 l/min. After six
weeks patients were switched to non-invasive ventilation (NIV) for another six weeks period.
Results: NHF led to significant decreases in resting pCO2. Between the devices we found no differences in pCO2 levels.
Conclusions: NHF may thus be an alternative treatment device in stable hypercapnic COPD patients.
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High-flow nasal cannulaBackground
Non-invasive ventilation (NIV) is a treatment option in
patients with chronic respiratory insufficiency, hypercap-
nia and COPD [1]. A recent study shows a decrease in
mortality by using NIV in patients with COPD [2]. In
some of these patients, the tolerance of ventilation by
mask is poor [3]. Nasal High-flow (NHF) represents a
new method to support breathing. NHF devices are able
to produce a heated and humidified airflow applied by
large bore nasal prongs. Some investigations revealed
benefits after extubation or cardiothoracic surgery in
hypoxemic patient in comparison with Venturi mask or
NIV [4, 5]. The study by Frat et al. documented a re-
duced intubation rate in severe hypoxemic patients. Sur-
prisingly, the 90 days mortality rate might be better in
NHF group in comparison with NIV and oxygen group
[6]. However, these studies closed out patients with
chronic respiratory insufficiency.
Several mechanisms could explain benefits of NHF. It´
s assured that NHF generates a low positive airway pres-
sure [7]. This could open atelectatic areas of the lung in
acute hypoxemic failure e.g. pneumonia or prevent
obstruction in chronic obstructive pulmonary disease.
Also a wash-out effect in the upper airways may be an-
other important mechanism [8]. Probably the dead space* Correspondence: highflow@web.de
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ume by NHF.
So, NHF exhibits various remarkable changes in
breathing efforts in COPD patients: hypercapnia declines
despite a decrease in respiratory rate and an increase in
tidal volume [7]. This results in a reduced minute vol-
ume. The decline in hypercapnia suggests an improve-
ment of alveolar ventilation. If this was verifiable NHF
could be an alternative treatment option in patients with
hypercapnia.
We initiated this clinical investigation in order to test
this hypothesis and also to describe the possible long-
time effectiveness of NHF in hypercapnic COPD
patients.Methods
The study was approved by local ethics committee and pa-
tients gave their written informed consent (No. 123-2009-
25052009; ClinicalTrials.gov Identifier: NCT02007772).
Eleven COPD patients with a BMI below 30 kg/m2 and
stable hypercapnia (≥ 50 mmHg) were included in the
study in 2009–2011 (Table 1). Patients received blood gas
analysis (BGA) for three times (further BGA also on ex-
acerbation, screening and baseline visit). Last two investi-
gations should exclude significant differences in capillary
pCO2. Stable hypercapnia or disease was defined as an
exacerbation-free time of six weeks. Hearth decompensa-
tion, acute illness or acute respiratory insufficiency wereticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
Table 1 Demographic data
Age 66.7 years
Gender m:f 7:4
FEV1 29.7 % pred.
FEV1%FVC 45.3 %
mean paCO2 53.7 mmHg
IPAP 16 cmH2O
EPAP 5.8 cmH2O
Fig. 1 capillary pCO2-levels
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exacerbation were included only if hypercapnia was still
persistent following six weeks after the end of exacerba-
tion. All other patients with hypercapnia in ambulatory
BGA were referred to a pulmonologist. To prevent day-
time variability in hypercapnia BGA was conducted at
same day-time on every visit.
The primary outcome parameter was capillary pCO2 up
to three hours following the end of treatment during the
night. After an initial visit, patients were adjusted on
NHF-system with a flow of 20 l/min with supplementary
oxygen (TNI oxy, TNI medical AG, Würzburg, Germany).
After 6 weeks patients were switched to NIV for another 6
weeks period (different systems). Patients were instructed
to maintain stable oxygen supplementation that had to be
stable during the 12 weeks of our study. Study visits in-
cluded lung function and blood gas analysis. Statistics
were done using Sigma Plot-software (Sigma Plot; Systat
Software GmbH, Ekrath, Germany). Patients were
instructed to use device more than 5 hours/ day. At the
start of study only one device for home care use was avail-
able (maximum flow 20l/min). Only TNI device was able
to provide accurate flow rates (measurements not shown).
Results and discussion
Six weeks of NHF led to significant decreases in resting
pCO2. After decreasing by NHF therapy, NIV was able
to preserve normocapnia. No differences in pCO2 were
observed between the two methods of non invasive ven-
tilatory support (Fig. 1).
NHF so far has no clear defined areas of indications.
Recently, published studies have described positive ef-
fects in acute hypoxemic failure [4–6]. Particularly with
regard to mortality, we believe NHF therapy demonstrates
significant benefits [6]. These studies recruited patients
without any chronic respiratory diseases and hypercapnia.
There are only few data available in such a patient cohort
[7]. To our knowledge, this is the first description of long-
time home care use in hypercapnic COPD patients.
Some authors focused on increased airway pressure,
decreasing breathing rate and improvements in oxygen-
ation. However, NHF effects appear more complex. As
shown by several authors, an increase in airway pressure
might be a helpful tool by supporting ventilation, butlevels of achievable pressures are low [7]. Despite of this,
significant effects on ventilation, with an increase in tidal
volume, decrease in breathing frequency, and reduction
in minute volume were observable [7]. As well shown in
an animal study by Frizzola et al. a wash-out of the
upper airways might be an important effect [8]. This
point separates NHF from NIV via face mask. Since
there was still a reduction in pCO2 NHF apparently in-
creases the efficiency of breathing [7].
In this study we found a significant decrease in capil-
lary pCO2 after using NHF for at least 5h/ day over 6
weeks. These results were similar to those in a following
period using NIV. This allows to postulate two main
findings. Firstly, the NHF decreases pCO2 despite of re-
duced minute ventilation. Further, it remains unclear
what are the main effects of working, but the reduction
in hypercapnia demonstrates that NHF is able to affect
alveolar ventilation. By using NIV normocapnia was
stabilized. One could speculate that NIV (with low
pressure levels) is able to decrease capillary pCO2 in
the same way.
There are several limitations to our study. First, patients
were not randomised and the study was monocentric. All
participants started with NHF. The initial hypercapnia
was moderate. Patients may have more difficulty tolerating
high NIV peak airway pressure levels. Because of small
sample size, a beta-error might be possibly. We only used
a low flow with 20 l/min and the reason was lack of avail-
ability of home care devices with constant flow.Conclusions
NHF may thus be an alternative treatment device in stable
hypercapnic COPD patients. A multicentric and rando-
mised investigation is now in planning and will be con-
ducted in order to verify the findings of this observational
investigation.
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